Register to the NASH Club and join our experts!

Prof. Gianluca Perseghin

Prof. Jeffrey Lazarus

Prof. Laurent Castéra

Prof. Massimo Pinzani

Prof. Cyrielle Caussy

Prof. Helen Jarvis

Prof. Jörn Schattenberg

Prof. Jose Luis Calleja

Prof. Wolf Peter Hofmann

Prof. Helena Cortez Pinto

Prof. Manuel Romero Gomez

Prof. Philip Newsome

Prof. Salvatore Petta
AGENDA
COURSE DESCRIPTION
CME CREDITS
AGENDA

EPISODE 1
NAFLD-NASH Epidemiology, diagnostic tools and strategies
Tuesday, 7th March 2023 ► 7pm – 8pm (GMT+1)

EPISODE 2
Creating referral pathways for the NAFLD/NASH patients beyond the liver clinic
Tuesday, 4th April 2023 ► 7pm – 8:15pm (GMT+2)

EPISODE 3
NASH: Current and future treatment options
Thursday, 4th May 2023 ► 7pm – 8pm (GMT+2)
COURSE DESCRIPTION
Chronic liver diseases (CLD) affect an estimated 1.5 billion people worldwide. Globally, the most common cause of CLD is non-alcoholic fatty liver disease (NAFLD) which is estimated to affect approximately 25% of the world’s adult population. Non-alcoholic Steatohepatitis (NASH) a progressive form of NAFLD which combines fatty liver, liver inflammation and liver damage, can lead in up to 25% of the cases to cirrhosis.
Join the 2023 NASH Club, a series of 3 full educational CME accredited interactive and hybrid event dedicated to all matters NAFLD-NASH. You will learn from 13 top experts from a wide range of medical specialties: Hepatolgists, Diabetologists, Endocrinologists, General practitioners and Gastroenterologists coming from different EU countries.
Overall Learning Objectives
- Learn more about the importance of liver diseases early screening, including in primary point of care and the latest available tools and techniques to perform liver exams.
- Closing the loop: Understand how coordination between medical specialties can help optimize patient journey and care.
- Get to know current NAFD-NASH treatment and future NASH treatment options including stage 3 drugs in process of approval.
CME CREDITS

NAFLD-NASH Epidemiology, diagnostic tools and strategies
Chair: Prof. Massimo Pinzani
Speakers: Prof. Jeffrey Lazarus, Prof. Laurent Castéra & Prof. Gianluca Perseghin

Prof. Massimo Pinzani

Prof. Jeffrey Lazarus

Prof. Laurent Castéra

Prof. Gianluca Perseghin
SESSION AGENDA
Chair: Prof. Massimo Pinzani
Introduction (Prof. Massimo Pinzani)
Epidemiology /public Health (Prof. Jeffrey Lazarus)
- Population impacted/ Why are patients underdiagnosed?
- Why NASH can become a big challenge for EU healthcare system?
Liver diseases diagnostics tools and strategies (Prof. Laurent Castéra)
- Tools and techniques
- Latest clinical studies and latest guidelines
NAFLD among T2D patients (Prof. Gianluca Perseghin)
Conclusion (Prof. Massimo Pinzani)

Creating referral pathways for the NAFLD/NASH patients beyond the liver clinic
Chair: Prof. Jörn Schattenberg
Speakers: Prof. Jose Luis Calleja, Prof. Cyrielle Caussy, Prof. Wolf Peter Hofmann & Prof. Helen Jarvis

Prof. Jörn Schattenberg

Prof. Jose Luis Calleja

Prof. Cyrielle Caussy

Prof. Wolf Peter Hofmann

Prof. Helen Jarvis
SESSION AGENDA
Chair: Prof. Jörn Schattenberg
Introduction (Prof. Jörn Schattenberg)
Role of primary care or GP in early screening and referral of NAFLD patients (Prof. Jose Luis Calleja)
Role of diabetologists/endocrinologists in screening NAFLD/NASH among T2D patients and patients with cardio metaboloic disease: epidemiology, clinical studies and guidelines (Prof. Cyrielle Caussy)
Roundtable: Multidisciplinary approach in practice (Prof. Wolf Peter Hofmann, Prof. Helen Jarvis, Prof. Cyrielle Caussy, Prof. Jose Luis Calleja)
Conclusion: Monitoring NAFLD patients (Prof. Jörn Schattenberg)

NASH: Current and future treatment options
Chair: Prof. Salvatore Petta
Speakers: Prof. Manuel Romero Gomez, Prof. Helena Cortez-Pinto & Prof. Philip Newsome

Prof. Salvatore Petta

Prof. Manuel Romero Gomez

Prof. Helena Cortez Pinto

Prof. Philip Newsome
SESSION AGENDA
Chair: Prof. Salvatore Petta
Introduction (Prof. Salvatore Petta)
Impact of lifestyle change: diet and exercise (Prof. Manuel Romero Gomez)
Treating comorbidities (Prof. Helena Cortez-Pinto)
Future treatment drugs in stage 3 (Prof. Philip Newsome)
Conclusion (Prof. Salvatore Petta)